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Fl Susceptibility to and Immunization against 
Tuberculosis 
K.F!WJ. McAdam. Medical Research Council Laboratories, Fajara, The 
Gambia, W Africa 
Exposure to Mycobarterium tuberculosis (M. rb) results in h c a l  tuber- 
culosis (TB) in approximately 10% of those mfected. The genetic 
and environmental factors which differentiate exposure, infection 
and dsease are not well defined. Crowding, poor socio-economic 
circumstances, malnutrition, alcoholism, diabetes, AIDS and other 
causes of immunocompromise are implicated. Susceptibility to my- 
cobacterial diseases has recently been associated with a mutation in 
the gamma interferon receptor gene and in The Gambia resistance to 
TI3 has been mapped to the vitamin D receptor gene. Lymphocyte 
proliferative responses to tuberculin are also heritable but Mantoux 
skin test responses do not predict protective immunity. The variable 
protective efficacy of BCG is partly explained by exposure to envi- 
ronmental mycobacteria and differences in BCG st ra ins  have iden- 
hfied various secreted antigens as virulence factors for M t b .  These 
antigens are being targeted in new TB vaccines which utilise recom- 
binant BCG, pox virus and naked DNA approaches. The need for 
surrogate markets of protective immunity is now an urgent priority, 
as vaccine candidates exceed the international capacity for cknical 
trials. 
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I S2111 Evolving epidemiology in communky-acquired 
respiratory tract infections in adults 
J.W.M. van der Meer, B.J. Kullberg. Universify Hospital Nijmegen, 
Nijmegen, The Netherlands 
Ear, nose and throat infections as well as upper respiratory tract 
mfections are very common. Critical investigations in this area have 
outlined the &culties in idenafylng the causative organism and the 
exact nature of the infection, and have cast doubt on the necessity 
to prescribe antibiotics for the majority of these condtions. 
Exacerbations of chronic bronchitis also are a common prob- 
lem in whch the infectious cause has become a matter of debate. 
In the Netherlands, many clinicians nowadays aim to combat the 
non-specific inhmmatory component, rather than the infection. 
Community acquired pneumonia (CAP) is also common, with 
estimated incidences of 2-4 per 1000. A variety of microorganisms 
may cause CAP. The insights in the epidemiology are hampered by 
the large proportion of patients in whom no causative organism can 
be identified. However, in view of the response to therapy most 
of these pneumonia can be considered as pneumococcal. For the 
clinical approach, Bothe et al. (EJCMID 1996; 15: 201) have pro- 
posed a simple clinical score to distinguish pneumococcal pneumonia 
from other CAP. They propose to use this as a guide for treatment: 
pneumococcal pneumonia in the Netherlands is shll treatable with 
benzylpenicib, most of the other CAP should receive a macmlide. 
I S212 1 Chlamydia pneumoniae: current knowledge 
R. Malinverni. Med. Policlinic, Inselspital, Bern, Switzerland 
Chlamydia pneumoniae (CP) is a common cause of commu- 
nity-acquired respiratory tract infection, in particular pneumonia. 
The majority of adults worldwide have serologic evidence of past 
mfection. Humans are the only known reservoir of CP and per- 
son to person transmission occurs via respiratory secretions. The 
incubation period of infection is several weeks. Most infections are 
asymptomatic. Cknical and radiological manifestations are nonspe- 
cific. Unfortunately, laboratory diagnosis is difficult and cumber- 
some, and most lnfections are not recognized. The natural history of 
CP mfection in thus only incompletely understood. Several chronic 
diseases, such as asthma, reactive arthritis and sarcoidosis have been 
presumptively linked to CF! Epidemiological morphologic and, most 
recently, culture data have associated CP with coronary heart disease. 
These chronic condtions are believed to be associated with CP in 
persistent state of mfection. As with other chlamydiae, there is in vitro 
and in uivo evidence for persistent CP mfection. An immunopatho- 
logic mechanism possible linked to expression of HSP by persistent 
chlamydia, is believed to be operative. Treatment recommendations 
are based on in v iho and experimental data, since no controlled tri- 
als of treatment have been performed. It is unclear under which 
circumstances CP can be eradicated. Research efforts are aimed at 
understandmg the role of CP in certain chronic conditions and the 
role of treatment for eradication of the organism. 
I s213 I Therapeutic Possibility of Macrolide for Chronic 
H. Kobayash. Kyorin Univ., Tokyo,Japan 
By investigating disease d e s t a t i o n  of airway b i o f h  &ease, most 
of which are chronically persisted by mucoid Pseudomoms amginosa, 
it was revealed that an excess antigen-antibody reaction where mu- 
coid-alginate acts as the antigen at site s m a l l  airway, and the resulting 
formation of immune complex are the important factors. The fac- 
tors which spechcally "link the state of airway biofilm disease to" 
the effects of 14 and 15 membered macrolides are the inhibition 
of immune reaction by alginate and their inhibitory effect on +- 
nate production being an antigen at the level of GMD (guanosine 
diphosphomannose dehydrogenose) that is a final enzyme of algi- 
nate synthetic pathway in Pseudomo~s amginosa. Furthermore, the 
specificity of macmlides on these effects is also discussed. 
Airway Biofilm Disease 
m1 Diagnostic and Management Strategies of 
Patients with Community Acquired Pneumonia 
(CAP) 
L.A. Mandell. McMaster University, Hamilton, Ontario, Canada 
CAP is a very common and potentially very serious disease. It is 
estimated that there are between 2-3 million cases of CAP yearly 
in the United States resulting in approximately 500,000 hospitalza- 
dons. The average m o d t y  is about 14% for hospitalized patiens 
and less than 1% for nonhospitalized patients. There is increasing 
awareness of the role of "atypical pathogens": M. pneumoniae, C. 
pneumoniae and Legionella as well as increasing resistance among 
bacterial pathogens such as S. pneumoniae. We now know that find- 
in5 from the history, physical examination and chest x-ray do not 
allow one to accurately predict the causative pathogen. Diagnostic 
tests include both noninvasive and invasive techniques but even with 
extensive diagnostic testing, a specific pathogen is not found in over 
50% of cases. Some data suggest that in severe CM, outcome is not 
changed even if the pathogen is determined. Management strategies 
and decisions regarding initial empiric therapy are based on assess- 
ment and stratification of the patient according to risk factors and 
severity of illness. Macrolides alone may be used in those previously 
well and less than 60 years of age. For those patients with comorbid 
illness or for those requiring admission to hospital, broader coverage 
in the form of beta-lactams, quinolones or aminoglycosides may be 
needed as well, depending upon the specific circumstances. 
